Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ESS
MCID: END031
MIFTS: 45

Endometrial Stromal Sarcoma (ESS)

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Endometrial Stromal Sarcoma

About this section

MalaCards integrated aliases for Endometrial Stromal Sarcoma:

Name: Endometrial Stromal Sarcoma 12 73 20 58 15 17 70
Ess 12 20
Endometrial Stromal Sarcoma, High Grade 12
Undifferentiated Endometrial Sarcoma 12
Stromal Sarcoma of the Corpus Uteri 58
Undifferentiated Stromal Sarcoma 70
Sarcoma, Endometrial Stromal 44
Sarcoma Endometrial Stromal 54

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:4226
MeSH 44 D018203
NCIt 50 C8973
SNOMED-CT 67 70555003
MESH via Orphanet 45 D018203
ICD10 via Orphanet 33 C54.1
UMLS via Orphanet 71 C0206630
Orphanet 58 ORPHA213711
UMLS 70 C0206630 C1710535
Sources

Summaries for Endometrial Stromal Sarcoma

About this section
GARD : 20 Endometrial stromal sarcoma is a rare form of cancer that occurs due to abnormal and uncontrolled cell growth in the uterus. Endometrial stromal sarcoma, specifically, develops in the supporting connective tissue (stroma) of the uterus. Signs and symptoms of the condition include abnormal uterine bleeding (i.e. bleeding that is not part of menstrual periods or bleeding after menopause); abdominal pain and/or distension; and frequent urination. The exact underlying cause of endometrial stromal sarcoma is currently unknown. Most cases occur sporadically in people with no family history of the condition. Treatment varies based on the severity of the condition but may include surgery, radiation therapy, chemotherapy, and/or hormone therapy.

MalaCards based summary : Endometrial Stromal Sarcoma, also known as ess, is related to vaginal endometrial stromal sarcoma and spindle cell sarcoma. An important gene associated with Endometrial Stromal Sarcoma is SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit), and among its related pathways/superpathways are Striated Muscle Contraction and Ovarian Infertility Genes. The drugs Doxorubicin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include breast, uterus and smooth muscle, and related phenotypes are cardiovascular system and muscle

Disease Ontology : 12 An endometrial stromal tumor that has material basis in connective tissue.

Wikipedia : 73 Endometrial stromal sarcoma is a malignant subtype of endometrial stromal tumor arising from the stroma... more...

Sources

Related Diseases for Endometrial Stromal Sarcoma

About this section

Diseases related to Endometrial Stromal Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 vaginal endometrial stromal sarcoma 33.0 YWHAE VIM SUZ12 PHF1 PGR MME
2 spindle cell sarcoma 32.9 VIM KIT DES ACTC1
3 endometrial stromal nodule 32.7 ZC3H7B YWHAE SUZ12 PHF1 NUTM2A MME
4 leiomyoma 32.1 VIM PGR MME KIT ESR1 DES
5 leiomyosarcoma 32.0 ZC3H7B VIM PGR KIT ESR1 DES
6 rare tumor 32.0 KIT DES ACTC1
7 endometrial stromal tumor 31.8 ZC3H7B YWHAE SUZ12 PHF1 PGR NUTM2B
8 adenomyosis 31.7 PGR MME ESR1 CYP19A1
9 cellular leiomyoma 31.7 SUZ12 MME JAZF1 DES
10 myoma 31.7 PGR MME KIT ESR1 CYP19A1
11 mesenchymal cell neoplasm 31.7 ZC3H7B MME KIT
12 leiomyomatosis 31.6 PGR KIT ESR1
13 intravenous leiomyomatosis 31.6 PGR MME ESR1 DES
14 carcinosarcoma 31.5 VIM PGR MME KIT DES ACTC1
15 leiomyoma, uterine 31.5 PGR ESR1 CYP19A1
16 smooth muscle tumor 31.4 VIM PGR MME KIT ESR1 DES
17 neurilemmoma 31.4 VIM KIT DES ACTC1
18 myxoid leiomyosarcoma 31.3 ZC3H7B YWHAE PGR MEAF6 MBTD1 EZHIP
19 adenosarcoma 31.3 VIM PHF1 PGR MME KIT JAZF1
20 endometriosis of ovary 31.3 PGR ESR1 CYP19A1
21 lymphangioleiomyomatosis 31.3 PGR ESR1 DES
22 hemangiopericytoma, malignant 31.2 VIM KIT DES ACTC1
23 endometrial adenocarcinoma 31.2 PGR MALAT1 ESR1
24 gastrointestinal stromal tumor 31.2 VIM KIT DES ACTC1
25 uterine carcinosarcoma 31.2 PGR MME KIT
26 cervical polyp 31.2 PGR MME DES
27 uterine corpus sarcoma 31.2 PGR KIT
28 embryonal sarcoma 31.1 VIM MALAT1 KIT DES
29 hemangioma 31.1 VIM PGR KIT ACTC1
30 endometrial hyperplasia 31.1 PGR ESR1 CYP19A1
31 fibroma 30.9 VIM MALAT1 DES ACTC1
32 glomus tumor 30.9 VIM DES ACTC1
33 adenofibroma 30.9 VIM MME INHA ACTC1
34 inflammatory myofibroblastic tumor 30.9 VIM KIT DES ACTC1
35 perivascular epithelioid cell tumor 30.9 VIM PGR MME KIT DES ACTC1
36 wilms tumor 1 30.9 VIM PGR MME ESR1 DES ACTC1
37 rhabdomyosarcoma 30.8 VIM MME KIT ESR1 DES ACTC1
38 cystadenocarcinoma 30.8 VIM PGR ACTC1
39 sarcoma, synovial 30.7 VIM KIT DES
40 empty sella syndrome 11.6
41 uterine corpus endometrial stromal sarcoma 11.4
42 cervical endometrial stromal sarcoma 11.4
43 sarcoma 11.4
44 euthyroid sick syndrome 10.9
45 endometriosis 10.9
46 uterine sarcoma 10.7
47 uterine corpus adenosarcoma 10.6 PGR MME ESR1
48 lymphangiomatosis 10.6 VIM PGR DES
49 cervical adenomyoma 10.6 PGR MME
50 congenital epulis 10.6 VIM PGR DES

Graphical network of the top 20 diseases related to Endometrial Stromal Sarcoma:



Diseases related to Endometrial Stromal Sarcoma
Sources

Symptoms & Phenotypes for Endometrial Stromal Sarcoma

About this section

MGI Mouse Phenotypes related to Endometrial Stromal Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.7 ACTC1 CYP19A1 DES ESR1 INHA KIT
2 muscle MP:0005369 9.23 ACTC1 CYP19A1 DES ESR1 KIT PGR
Sources

Drugs & Therapeutics for Endometrial Stromal Sarcoma

About this section

Drugs for Endometrial Stromal Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Ifosfamide Approved Phase 3 3778-73-2 3690
4
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
5
Cyproheptadine Approved Phase 3 129-03-3 2913
6
Liposomal doxorubicin Phase 3 31703
7 Antibiotics, Antitubercular Phase 3
8 Anti-Bacterial Agents Phase 3
9
Isophosphamide mustard Phase 3 100427
10 Alkylating Agents Phase 3
11 Gastrointestinal Agents Phase 3
12 Neurotransmitter Agents Phase 3
13 Anti-Allergic Agents Phase 3
14 Histamine Antagonists Phase 3
15 Dermatologic Agents Phase 3
16
Histamine Phosphate Phase 3 51-74-1 65513
17 Histamine H1 Antagonists Phase 3
18
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
19
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
20
Ipilimumab Approved Phase 2 477202-00-9
21
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
22
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
23
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
27
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
28
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
29
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
30
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
31
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
32
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
33
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
34
nivolumab Approved Phase 2 946414-94-4
35
Saracatinib Investigational Phase 2 379231-04-6
36
Trebananib Investigational Phase 2 894356-79-7
37 Tubulin Modulators Phase 2
38 Antimitotic Agents Phase 2
39 Albumin-Bound Paclitaxel Phase 2
40 Anti-Infective Agents Phase 2
41 Angiogenesis Inhibitors Phase 2
42 Immunosuppressive Agents Phase 2
43 Immunologic Factors Phase 2
44 Imatinib Mesylate Phase 1, Phase 2 220127-57-1 123596
45 Protein Kinase Inhibitors Phase 1, Phase 2
46 Antiemetics Phase 2
47 Hydrocortisone 17-butyrate 21-propionate Phase 2
48 glucocorticoids Phase 2
49 Hydrocortisone hemisuccinate Phase 2
50 Anti-Inflammatory Agents Phase 2

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
2 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
4 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
5 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
6 A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool Unknown status NCT02982486 Phase 2 Ipilimumab;Nivolumab
7 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
8 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
9 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
10 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
11 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
12 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
13 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
14 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
15 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
16 A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium Completed NCT01210222 Phase 2
17 A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212 Completed NCT02150213 Phase 2 BGG492
18 Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS) Completed NCT00505739 Phase 2 Mifepristone
19 Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS Recruiting NCT03624244 Phase 2 Aromatase Inhibitors
20 An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies Recruiting NCT03926936 Phase 2 Fulvestrant
21 Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer Recruiting NCT03241745 Phase 2 Nivolumab
22 A Phase 1 Study of Metronomic Selinexor in Select Soft Tissue Sarcomas and Split Dosing of Selinexor in All Soft Tissue Sarcomas Recruiting NCT04811196 Phase 1 Selinexor
23 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
24 Prospective Study of Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis Recruiting NCT04557969

Search NIH Clinical Center for Endometrial Stromal Sarcoma

Cochrane evidence based reviews: sarcoma, endometrial stromal

Sources

Genetic Tests for Endometrial Stromal Sarcoma

About this section
Sources

Anatomical Context for Endometrial Stromal Sarcoma

About this section

MalaCards organs/tissues related to Endometrial Stromal Sarcoma:

40
Breast, Uterus, Smooth Muscle, Ovary, Kidney, Liver, Cervix
Sources

Publications for Endometrial Stromal Sarcoma

About this section

Articles related to Endometrial Stromal Sarcoma:

(show top 50) (show all 1071)
# Title Authors PMID Year
1
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 61 54
18565690 2008
2
Aromatase inhibitors in gynecologic cancers. 54 61
17826626 2007
3
Hormonal therapy of endometrial stromal sarcoma. 54 61
17545798 2007
4
Pulmonary metastasis of endometrial stromal sarcoma. 54 61
17317938 2006
5
Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma. 61 54
15963815 2005
6
Utility of MIB-1 and estrogen and progesterone receptor in distinguishing between endometrial stromal sarcomas and endometrial stromal nodules, highly cellular leiomyomas. 54 61
15823122 2005
7
Distinction of endometrial stromal sarcomas from 'hemangiopericytomatous' tumors using a panel of immunohistochemical stains. 54 61
15309019 2005
8
Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. 54 61
15516445 2004
9
Recurrence of prolactin-producing endometrial stromal sarcoma with sex-cord stromal component treated with progestin and aromatase inhibitor. 61 54
15297205 2004
10
Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. 54 61
15084842 2004
11
Low-grade endometrial stromal sarcoma: hormonal aspects. 61 54
12821359 2003
12
Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. 61 54
12218209 2002
13
Cytologic diagnosis of low grade endometrial stromal sarcoma by staining for estrogen and progesterone receptors. 61 54
12146057 2002
14
Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. 61 54
11865845 2002
15
Endometrial stromal sarcoma: objective response to letrozole. 54 61
11531300 2001
16
Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. 61 54
11353058 2001
17
Effects of interleukin-4 on the in-vitro production of cytokines by human endometrial stromal cells. 54 61
11228246 2001
18
Estrogen receptor expression in an endometrial stromal sarcoma after tamoxifen therapy. 54 61
11874071 2001
19
Effects of interferon-gamma on cytokine production by endometrial stromal cells. 54 61
9806291 1998
20
Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness. 61 54
1562530 1992
21
Steroid hormone receptors in endometrial stromal sarcomas. A biochemical and immunohistochemical study. 54 61
1371902 1992
22
Myogenous phenotype of epithelial-like areas in endometrial stromal sarcomas. 61 54
2001155 1991
23
Immunohistochemistry of endometrial stromal sarcoma. 61 54
1706303 1991
24
Extra-uterine endometrial stromal sarcoma of the left adnexa and distal ureter: A case report. 61
33553557 2021
25
Cervical malignant mixed mesonephric tumour: A case report with local recurrence after six-years and next-generation sequencing analysis with particular reference to the ataxia telangiectasia mutated gene. 61
33680116 2021
26
Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma. 61
33063261 2021
27
Metastatic low-grade endometrial stromal sarcoma after 24 years: A case report and review of recent molecular genetics. 61
32910526 2021
28
Molecular pathogenesis and prognostication of "low-grade'' and "high-grade" endometrial stromal sarcoma. 61
33099834 2021
29
Metastatic endometrial stromal sarcoma: A rare cause of right-sided intracardiac mass. 61
33651415 2021
30
SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. 61
33720083 2021
31
Low-grade endometrial stromal sarcoma: A Turkish uterine sarcoma group study analyzing prognostic factors and disease outcomes. 61
33375988 2021
32
A Giant Leiomyoma with Massive Cystic Hydropic Degeneration Mimicking an Aggressive Neoplasm: A Challenging Case with a Literature Review. 61
33785706 2021
33
[Uterine malignant perivascular epithelioid cell tumor (PEComa): Two case reports]. 61
32646778 2021
34
Uterine Sarcomas: A Retrospective Analysis of a Cohort of 62 Patients. 61
33747651 2021
35
Fertility-sparing surgeries without adjuvant therapy through term pregnancies in a patient with low-grade endometrial stromal sarcoma: A case report. 61
33585648 2021
36
High-grade endometrial stromal sarcoma versus undifferentiated uterine sarcoma: a Turkish uterine sarcoma group study-001. 61
33392719 2021
37
Corrigendum to "Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images". 61
33628546 2021
38
Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. 61
32889887 2021
39
The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study. 61
33503190 2021
40
MR imaging findings of unusual leiomyoma and malignant uterine myometrial tumors: what the radiologist should know. 61
33517507 2021
41
Endometrial Sarcoma Metastasis to the Pterygopalatine Fossa: A Case Report and Review of the Literature. 61
33415993 2021
42
Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR. 61
33718245 2021
43
Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases. 61
33093955 2020
44
Spontaneous pneumothorax secondary to an endometrial stromal sarcoma. 61
33271115 2020
45
Low-grade Endometrial Stromal Sarcoma Presenting as a Sigmoid Mass. 61
33361707 2020
46
Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma. 61
33210235 2020
47
Does iatrogenic tumor rupture during surgery have prognostic implications for the outcome of uterine sarcomas? 61
32948637 2020
48
Endometrial stromal sarcoma extending to the pulmonary artery: A rare case report. 61
33344553 2020
49
Fertility-sparing management of low-grade endometrial stromal sarcoma: analysis of an institutional series, a population-based analysis and review of the literature. 61
33313103 2020
50
Endometrial stromal sarcoma: A review of rare mesenchymal uterine neoplasm. 61
32830415 2020
Sources

Variations for Endometrial Stromal Sarcoma

About this section
Sources

Expression for Endometrial Stromal Sarcoma

About this section
Search GEO for disease gene expression data for Endometrial Stromal Sarcoma.
Sources

Pathways for Endometrial Stromal Sarcoma

About this section

Pathways related to Endometrial Stromal Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Striated Muscle Contraction 1 65
11.19 VIM DES ACTC1
2
Ovarian Infertility Genes 1
10.3 PGR INHA CYP19A1
3
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
9.56 ESR1 CYP19A1
Sources

GO Terms for Endometrial Stromal Sarcoma

About this section

Cellular components related to Endometrial Stromal Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ESC/E(Z) complex GO:0035098 8.62 SUZ12 PHF1

Biological processes related to Endometrial Stromal Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 male gonad development GO:0008584 9.5 KIT INHA ESR1
2 positive regulation of phospholipase C activity GO:0010863 9.26 KIT ESR1
3 intracellular steroid hormone receptor signaling pathway GO:0030518 9.16 PGR ESR1
4 negative regulation of histone H3-K27 methylation GO:0061086 8.96 PHF1 EZHIP
5 muscle filament sliding GO:0030049 8.8 VIM DES ACTC1

Molecular functions related to Endometrial Stromal Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 methylated histone binding GO:0035064 9.13 SUZ12 PHF1 MBTD1
2 RNA polymerase II transcription corepressor binding GO:0001226 8.8 SUZ12 PHF1 ESR1
Sources

Sources for Endometrial Stromal Sarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....